glp-1 ra mechanism of action Consensus Recommendations on Use in the Management Type 2 Diabetes Mellitus: South Asian Task Force | Diabetes Therapy Glucagon-like peptide-1 receptor: mechanisms and
Description
Immunogenicity: Because these are peptides, the body can form anti-drug antibodies

A 2025 analysis found that GLP-1 agonists given for diabetes were associated with a reduced risk of substance use among hundreds of thousands of United States Veterans and a 2024 examination of over 500k patients 4 Qeadan, F., McCunn, A., & Tingey, B

infusion of GLP-1 decreased water consumption by 36% in response to i.v
Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H-U

Acta Materia Med

15 Phase II trials targeting MASH have shown that treatment with SEMA 0.4 mg daily for 72 weeks resulted in more patients with liver fibrosis stage F2/F3 achieving improvement in MASH without progression of liver fibrosis (odds ratio = 6.87, 95% CI = 2.6017.63) compared to placebo
